MedPath

AZURITY PHARMACEUTICALS INDIA LLP

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

7

FDA:7

Drug Approvals

DEXMEDETOMIDINE HYDROCHLORIDE

Approval Date
Jun 28, 2023
FDA

BACLOFEN

Approval Date
Jun 16, 2023
FDA

VIVIMUSTA

Approval Date
Dec 7, 2022
FDA

MERZEE

Approval Date
Jun 30, 2022
FDA

TESTOSTERONE

Approval Date
Jun 12, 2022
FDA

DEXMEDETOMIDINE HYDROCHLORIDE

Approval Date
Apr 15, 2021
FDA

Icatibant

Approval Date
Jan 28, 2021
FDA

Clinical Trials

No trials found

News

Federal Circuit Reverses PTAB Decision on Brimonidine Eye Redness Patent in Landmark Claim Construction Ruling

The Federal Circuit reversed the Patent Trial and Appeal Board's claim construction of U.S. Patent No. 8,293,742, which covers methods for reducing eye redness using brimonidine as the sole active ingredient.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.